Supera

Vascular **Mimetic** Implant

Mimics the natural structure and movement of the anatomy[1,2]

Provides excellent strength and flexibility for a more durable solution[3,4]

Clinically Proven*

Change the Rules



SFA

POP
POPLITEAL

Abbott
A Promise for Life

A New Class of SFA Technology …

The Supera Vascular Mimetic Implant mimics the anatomy's natural movement, resulting in sustained patency and durable outcomes, even in calcified and long lesions.

… that Mimics the Natural Structure and Movement of the Anatomy

The natural environment of the SFA and proximal popliteal anatomy is highly dynamic and characterized by twisting, bending, shortening and compression. The native vasculature reacts seamlessly to these forces to maintain unhindered blood flow.

The Supera Vascular Mimetic Implant supports the natural movement of the vessel:



… with the Greatest Strength and Flexibility[3,4]

Supera offers the highest levels of both strength and flexibility minimizing traditionally accepted design trade-offs.

Supera provides the strength needed to treat highly calcified lesions – 9 kg of compression resistance – with the lowest chronic outward force.

More than **4x** the compression resistance with the least chronic outward force[3]

… that is Clinically proven. Again and Again.

The Supera Vascular Mimetic Implant has demonstrated high patency again and again. Supera has been analyzed in 1,450 real-world patients worldwide in the SUPERB pivotal trial and seven retrospective analyses, across the SFA and popliteal arteries, and in patients ranging from claudicants to critical limb ischemia.[5,6]

Zero fractures at one year across all trials[5,6,7]

86.2% primary patency (K-M) at 1 year in the SUPERB trial

12 Month Data Across SFA trials by Lesion Length*



* Scheinert, D. Results from the SUPERA 500 Registry. LINC 2013. Clinical data on file at Abbott. Rocha Singh, K. Performance Goals and Endpoint Assessments for Clinical Trials of Femoropopliteal Bare Nitinol Stents in Patients With Symptomatic Peripheral Arterial Disease. Catheterization and Cardiovascular Interventions 69:910–919 (2007). Everflex Instructions for Use. Bosiers, M. Durability 200 Study. LINC 2011. Bosiers, et al. Nitinol Stent Implantation in Long Superficial Femoral Artery Lesions: 12-Month Results of the DURABILITY I Study. J ENDOVASC THER. 2009; 16:261–269. Schroe, H. Absolute BELGIAN study. CIRCE 2008. "Schillinger, M. Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery. N Engl J Med 2006;354:1879-88." Dake, M. Paclitaxel-Eluting Stents Show.. Circ Cardiovasc Interv. 2011 Oct 1;4(5):495-504. IFU, Complete SE. IFU, Lifestent. Ansel G. STROLL Trial. LINC 2013. Ansel G. One-year interim results: Gore VIBRANT clinical study. LINC 2010. Saxon, R. One-year results: Gore VIPER clincial study. J Vasc Interv Radiol 2013; 24:165-173.

Ordering Information

	Implant Diameter (mm)	Implant Length (mm)									
		20	30	40	60	80	100	120	150	180	200
6F 80cm	4	SE-04-020-080-6F	SE-04-030-080-6F	SE-04-040-080-6F	SE-04-060-080-6F	SE-04-080-080-6F	SE-04-100-080-6F	SE-04-120-080-6F	SE-04-150-080-6F		
	5	SE-05-020-080-6F	SE-05-030-080-6F	SE-05-040-080-6F	SE-05-060-080-6F	SE-05-080-080-6F	SE-05-100-080-6F	SE-05-120-080-6F	SE-05-150-080-6F	SE-05-180-080-6F	SE-05-200-080-6F
	6	SE-06-020-080-6F	SE-06-030-080-6F	SE-06-040-080-6F	SE-06-060-080-6F	SE-06-080-080-6F	SE-06-100-080-6F	SE-06-120-080-6F	SE-06-150-080-6F	SE-06-180-080-6F	SE-06-200-080-6F
	7	SE-07-020-080-6F	SE-07-030-080-6F	SE-07-040-080-6F	SE-07-060-080-6F	SE-07-080-080-6F	SE-07-100-080-6F				

	Implant Diameter (mm)	Implant Length (mm)									
		20	30	40	60	80	100	120	150	180	200
6F 120cm	4	SE-04-020-120-6F	SE-04-030-120-6F	SE-04-040-120-6F	SE-04-060-120-6F	SE-04-080-120-6F	SE-04-100-120-6F	SE-04-120-120-6F	SE-04-150-120-6F		
	5	SE-05-020-120-6F	SE-05-030-120-6F	SE-05-040-120-6F	SE-05-060-120-6F	SE-05-080-120-6F	SE-05-100-120-6F	SE-05-120-120-6F	SE-05-150-120-6F	SE-05-180-120-6F	SE-05-200-120-6F
	6	SE-06-020-120-6F	SE-06-030-120-6F	SE-06-040-120-6F	SE-06-060-120-6F	SE-06-080-120-6F	SE-06-100-120-6F	SE-06-120-120-6F	SE-06-150-120-6F	SE-06-180-120-6F	SE-06-200-120-6F
	7	SE-07-020-120-6F	SE-07-030-120-6F	SE-07-040-120-6F	SE-07-060-120-6F	SE-07-080-120-6F	SE-07-100-120-6F				
7F 120cm	8	SE-08-020-120-G3	SE-08-030-120-G3	SE-08-040-120-G3	SE-08-060-120-G3	SE-08-080-120-G3	SE-08-100-120-G3				

Delivery System



Stent Material



Competitors tested include **Complete SE, Astron Pulsar-18, Maris Deep, Innova, Epic, Zilver, EverFlex, LifeStent, Misago,** and **S.M.A.R.T.**

1. Data on file at Abbott Vascular.

2. Independent lab bench-top testing, data on file at Abbott Vascular.

3. 9 kg compression resistance for 5 x 100 mm Supera implant to achieve 53% compression. Four times the compression resistance of all other competitors. All other products compressed 53% with less than 2.25 kg applied. Data on file at Abbott Vascular.

4. Flexibility is defined as kink resistance. Supera implant demonstrated lowest kink resistance for 5 and 6 x 100 mm implants as compared to 6 x 100 mm standard nitinol stents in a tube. Data on file at Abbott Vascular.

5. Garcia, L., Rosenfield, K., et al., SUPERB Pivotal IDE Trial, 12-Month results, TCT 2012.

6. Scheinert, et al., Real world perspectives of treating complex SFA-Pop lesions, Results from the SUPERA-500 (including Leipzig SFA, Leipzig Popliteal and S500 LL) Registry, LINC 2013; Goverde, et al., AURORRA registry: Experience with high radial force interwoven nitinol stents in femoro-popliteal arteries, LINC 2013; Molenaar, et al., Interwoven self-expanding nitinol stents for long complex SFA and popliteal lesions CWZ, LINC 2012; Goltz, et al., Endovascular Treatment of Popliteal Artery Segments P1 and P2 in Patients with Critical Limb Ischemia, J Endovasc Ther 2012;19:450-456; Chan, et al., HK Single-centre Results of Femoro-popliteal Revascularization using Helical Interwoven Nitinol Stents, LINC AP 2013; Pacanowski, et al., RESTORE: Interwoven Stents in the Real World, The Initial United States Experience with the Use of the Supera Stent in the SFA and Popliteal Artery, LINC 2013; Kovach, R., SAKE, Supera Interwoven Nitinol Stent Outcomes in Above-Knee Interventions: A Single Center Experience, LINC 2013; Leon, et al., Preliminary Results of the Initial United States Experience with the Supera Woven Nitinol Stent in the Popliteal Artery. J Vasc Surg 2013; 57:1014-22.

7. Zero fractures at one year across all trials and registries.

Please contact your local representative for more information. **Abbott Vascular International BVBA**, Park Lane, Culliganlaan 2B, 1831 Diegem, BELGIUM

Tests performed by and data on file at Abbott Vascular. All drawings are artist's representations only and should not be considered as an engineering drawing or photograph. Photo(s) on file at Abbott Vascular.

Products intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for instructions for use, warnings and potential complications associated with use of this device.

Information contained herein is for distribution for Europe, Middle East and Africa ONLY. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force. For more information, visit our website at **abbottvascular.com**

Abbott Vascular